Review Papers Claim by Claim

Key strengths (evidence-based)

• AAV-compatible compact repressor: uses SaCas9 (3.2 kb) deactivated and fused to KRAB, enabling a two-vector AAV8 system compatible with full-length promoters/pA signals — a pragmatic solution to the AAV packaging limit Ran et al., Nature 2015 (SaCas9 size & AAV)
• Physiologic phenotype measured: Pcsk9 protein and LDL reductions provide direct phenotypic readouts linking transcriptional repression to an established clinical biomarker axis (cholesterol regulation) rather than only transcript measures Thakore et al., Nature Commun. 2018 (Pcsk9 phenotype measurements)
• Durability shown: single low-dose treatment yielded Pcsk9 suppression measurable through 24 weeks (sustained, though partial) demonstrating long-term episomal AAV expression can support transcriptional repression in post-mitotic tissue Thakore et al., durable Pcsk9 repression (24 weeks)

Key weaknesses, limitations and blindspots

• Small in vivo n and biological variability: n=4 mice per group limits power to detect modest or heterogeneous effects and increases risk that stochastic immune responses or AAV batch effects drive group differences Thakore et al., sample size (n=4)
• Host immune/transcriptional confound: dSaCas9-KRAB expression elicited immune gene enrichment and transient ALT elevation, complicating interpretation of downstream transcriptional changes as direct KRAB-mediated on-target repression vs secondary inflammation or AAV effects; the authors acknowledge this and show immune enrichment is associated primarily with dSaCas9-KRAB expression (not gRNA alone) Thakore et al., immune response to dSaCas9-KRAB
• Off-target analysis limited: off-target assessment combined RNA-seq with Cas-OFFinder predicted sites but lacked ChIP-seq for dCas9-KRAB binding or locus-specific chromatin assays across timepoints, leaving open low-frequency or distal epigenetic effects not captured by bulk RNA-seq Thakore et al., off-target analysis using Cas-OFFinder only
• Tissue scope & translational gaps: experiments limited to liver (AAV8 tropic); immune responses and AAV pharmacology differ across species and tissues so human translation needs cautious dose/tolerability reassessment and immunogenicity mapping — a standard but crucial limitation.

Technical reproducibility & data availability

Methods are described in detail (plasmids on Addgene: dSaCas9-KRAB constructs available) and RNA-seq raw data are deposited (GEO:GSE109608), enabling reproduction of RNA-seq analyses and re-use of constructs — however, in vivo AAV batch/titer specifics and small-group biological variance will need careful matching for reproduction Thakore et al., methods and data availability (Addgene, GEO)

Context with prior work

The study builds on two key concepts: (1) CRISPR-dCas9 epigenetic effectors (CRISPRi/CRISPRa) pioneered in vitro Qi et al., Cell 2013 (CRISPRi foundation) and (2) SaCas9 being AAV-compatible for in vivo editing (Ran et al., 2015) cited above; Thakore et al. integrate these to deliver dSaCas9-KRAB as an AAV-compatible repressor in adult mice Ran et al., Nature 2015 (SaCas9 enabling AAV)

Where evidence could change conclusions (falsifiability)

• If independent larger cohorts fail to reproduce long-term Pcsk9 suppression at low AAV doses while matching immune readouts, the durability claim weakens.
• If ChIP-seq maps reveal widespread dSaCas9-KRAB binding at distal regulatory loci that correlate with transcriptional changes, specificity claims would be challenged.
• If human hepatocyte in vitro or non-human primate in vivo work shows stronger immunogenicity or liver toxicity at equivalent exposures, translational feasibility would be limited.

Concrete recommendations to strengthen follow-up work

1. Expand in vivo group sizes, include both sexes, and add independent AAV production lots to control batch effects.
2. Perform dSaCas9 ChIP-seq (or CUT&RUN) in treated livers to map dCas9 occupancy and directly test off-target binding vs RNA-seq changes.
3. Run longer follow-up (≥1 year) and include non-human primate tolerability/immune profiling before clinical translation planning.
4. Test immune-sparing designs: tissue-specific promoters, engineered less-immunogenic Cas9 variants, or transient immunomodulation.

Short technical note on interpreting dose-response

The paradoxical observation — stronger initial repression at high dose but poorer durability — is consistent with dose-triggered immune-mediated clearance of transduced cells or suppressed expression; this underscores that maximal dose is not always optimal for durable epigenetic modulation in vivo Thakore et al., dose vs durability observation

Accessible data & resources

Primary paper DOI: 10.1038/s41467-018-04048-4 (full methods & supplementary data). RNA-seq raw data: GEO GSE109608. Addgene plasmids referenced in methods for reagents.